Can the ResMed share price smash its all-time high?

The ResMed Inc. (ASX: RMD) share price is down 18% from its all-time high, which may represent a buying opportunity.

A leading company in an important industry ResMed Inc. (ASX: RMD) is a leader in the sleep treatment market, with a range of cloud enabled products designed to care for people with sleep apnea, COPD and other chronic diseases. This leading position has resulted in the the company's share price growing at an annualised rate of 17.9% over the last decade, excluding dividends.

Healthcare continues to rise in importance as a major topic on social and political agendas around the world. Aging populations, an increase in chronic disease, growing costs and a shortage of doctors require better solutions and technologies.

Despite this the ResMed share price dropped after an underwhelming second quarter result, delivered on 24 January 2019. For Q2 the company delivered 9% revenue growth to $651 million (on a constant currency basis) and Non-GAAP operating profit growth of 15%, to $181 million.

a woman

Capital allocation

It is pleasing to see the company focus on the long term, with a stated strategy to 2025. ResMed invests approximately 7% of its revenue back into research & development. This helps the company maintain and grow its market share through its range of quality products.

ResMed isn't just investing in itself however, with a number of acquisitions being made in recent years. The company has made numerous acquisitions in its key field of sleep apnea – most recently the purchase of South Korean based HB Healthcare, on 7 March 2019. ResMed has also invested in emerging areas such as out-of-hospital software-as-a-service offerings, through its 5 November 2018 acquisition of MatrixCare. The strategic decisions on the growing digital health and software-as-a-service trends highlights an understanding of where healthcare is moving.

The patent dispute

One concern that was lingering with ResMed until 21 February 2019 was the ongoing patent infringement dispute between ResMed and Fisher & Paykel Healthcare Corp Limited (ASX: FPH). In February both companies agreed to settle all of their outstanding patent infringement disputes, in all venues around the world. Most of the terms are confidential however, all ongoing proceedings ceased and both companies are paying their own legal expenses.

Foolish bottom line

ResMed has a long runway for growth, with sleep apnea being a grossly under-diagnosed medical condition. As doctors and potential patients alike become more aware of the condition, ResMed should see a steady increase in the adoption of its CPAP machines and its share price.

ResMed will report its third quarter FY19 earnings on 2 May 2019.

If you like the sound of ResMed, here are some other high quality growth companies.

Motley Fool contributor Lloyd Prout owns shares in ResMed. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

Codan share price A dismayed kid dressed as a scientist stands with his back to a rocket crashed into the ground
Share Fallers

Xero shares crash to a 7-year low after a brutal sell-off

The decline has wiped out years of share price gains.

Read more »

Two miners at a mine site on their tablets, with mining machinery behind them.
Share Fallers

Why has the Mineral Resources share price fallen 12% this week?

It’s been another tough week for Mineral Resources shareholders.

Read more »

A man holds his hand to his chin with a furrowed brow, making an expression of puzzlement or confusion.
Share Fallers

Top 3 ASX 200 shares now below their 200-day moving average

Are these businesses still a buy?

Read more »

A young man clasps his hand to his head with a pained expression on his face and a laptop in front of him.
Share Fallers

What are the most shorted ASX shares on the market right now?

Two names, two opposite bear cases.

Read more »

An arrow crashes through the ground as a businessman watches on.
Share Fallers

Warning: Corporate Travel shares have crashed 80%. What on earth just happened?

An 80% crash has left investors asking what went so wrong.

Read more »

Stressed businessman sits in panic amid digital stock market financial background.
Share Fallers

The five worst-performing ASX 200 shares in August unmasked

Investors sent these five ASX shares crashing 17% to 23% in August. But why?

Read more »

Stressed businessman sits in panic amid digital stock market financial background.
Share Fallers

Why Megaport, Lendlease and JB Hi-Fi shares all crashed 14% to 15% this week

ASX investors punished Lendlease, Megaport, and JB Hi-Fi this week. But why?

Read more »

Woman checking out new laptops.
Consumer Staples & Discretionary Shares

Down 14% today: Are JB Hi-Fi shares now a bargain-bin buy?

Could JB's plunge mean a bargain buy?

Read more »